At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 860 enrolled
Drug / intervention
NAFT-600 (naftin 2 % gel) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
In Brief
A Phase 3 clinical trial evaluating NAFT-600 (naftin 2 % gel) and Placebo for Tinea Pedis. Completed, enrolled 860 participants across 23 sites.
Detailed Summary
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinea Pedis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionNov 2011
Study CompletionDec 2011
TodayJul 2026
First PostedFeb 7, 2011
Enrollment StartFeb 1, 2011
Primary CompletionNov 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.4 years ago
Interventions
NAFT-600 (naftin 2 % gel)drug
Topical; applied once daily for two weeks
Placebodrug
Topical; applied once daily for two weeks.